A Multinational, Multicenter, Randomized, Double-blind, Study in Areas of High Pneumococcal Resistance Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Ketek Telithromycin Once Daily for 7 Days, or Zithromax Azithromycin Once Daily for 5 Days.

Trial Profile

A Multinational, Multicenter, Randomized, Double-blind, Study in Areas of High Pneumococcal Resistance Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Ketek Telithromycin Once Daily for 7 Days, or Zithromax Azithromycin Once Daily for 5 Days.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2011

At a glance

  • Drugs Azithromycin; Telithromycin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 24 Oct 2006 Status change
    • 29 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top